Published

TCB-2 [(7R)-3-bromo-2, 5-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine]: A hallucinogenic drug, a selective 5-HT receptor pharmacological tool, or none of the above?

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Neuropharmacology
Date: 2018-11-01
Source: PubMed
DOI: 10.1016/j.neuropharm.2017.10.004
PubMed: 28987938

Authors

Di Giovanni G De Deurwaerdère P

Watch author

Derived topics and classifications

psilocybin Mechanism of Action Receptor Pharmacology Review Article Animal Study Review Article

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression: a Pilot Clinical Neuroimaging StudyClinicalTrials.gov · 2025-08-20 Maddening Therapies: How Hallucinogens Morphed into Novel TreatmentsCurrent psychiatry · 2017-01-01 Molecular Structure, Reactivity and Spectroscopic Properties of Hallucinogens Psilocybin, Mescaline and their Derivatives - A Computational StudyLetters in Applied NanoBioScience · 2022-09-17 Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term MeditatorsClinicalTrials.gov · 2014-05-20